Stock Events

Stock Events

Aclaris Therapeutics 

$4.2
48
+$0.06+1.45% Today

Statistics

Day High
4.22
Day Low
4.01
52W High
4.89
52W Low
1.05
Volume
928,283
Avg. Volume
2,405,634
Mkt Cap
455.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.01
-0.68
-0.34
-0.01
Expected EPS
-0.155714
Actual EPS
N/A

Financials

-705.48%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
37.44MRevenue
-264.13MNet Income

Analyst Ratings

$12.00Average Price Target
The highest estimate is 16.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACRS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the dermatology space, particularly in treatments for conditions like atopic dermatitis, which overlaps with Aclaris's focus areas.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, through its acquisition of Allergan, has a strong presence in dermatology and aesthetics, directly competing with Aclaris's pipeline of skin condition treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a portfolio that includes treatments for psoriasis and other skin conditions, making it a direct competitor to Aclaris in the dermatological treatment market.
Journey Medical
DERM
Mkt Cap213.64M
Journey Medical Corporation (formerly Dermira) focuses on dermatological solutions, including therapies for skin conditions that Aclaris also targets.
Novartis
NVS
Mkt Cap237.61B
Novartis offers products for skin conditions such as psoriasis, directly competing with Aclaris's dermatology-focused pipeline.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a broad portfolio that includes treatments for skin diseases, positioning it as a competitor in the dermatology market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops treatments for psoriasis and other skin conditions, competing with Aclaris.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has entered the dermatology market with treatments for conditions like atopic dermatitis, making it a competitor to Aclaris.
Merck
MRK
Mkt Cap214.76B
Merck & Co. has a diverse pharmaceutical portfolio that, while not focused on dermatology, includes treatments that could compete with Aclaris's products in broader therapeutic areas.

About

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Show more...
CEO
Dr. Neal S. Walker D.O., M.D.
Employees
61
Country
US
ISIN
US00461U1051

Listings

LSE
GB
0H8T.LSE
XNAS
US
ACRS
F
DE
8AT.F
BOATS
BOATS
ACRS.BOATS

0 Comments

Share your thoughts

FAQ

What is Aclaris Therapeutics stock price today?▼
The current price of ACRS is $4.2 USD — it has increased by +1.45% in the past 24 hours. Watch Aclaris Therapeutics stock price performance more closely on the chart.
What is Aclaris Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aclaris Therapeutics stocks are traded under the ticker ACRS.
Is Aclaris Therapeutics stock price growing?▼
ACRS stock has risen by +19.32% compared to the previous week, the month change is a +37.7% rise, over the last year Aclaris Therapeutics has showed a +172.73% increase.
What is Aclaris Therapeutics market cap?▼
Today Aclaris Therapeutics has the market capitalization of 455.05M
When is the next Aclaris Therapeutics earnings date?▼
Aclaris Therapeutics is going to release the next earnings report on May 12, 2026.
What were Aclaris Therapeutics earnings last quarter?▼
ACRS earnings for the last quarter are -0.16 USD per share, whereas the estimation was -0.14 USD resulting in a -10.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aclaris Therapeutics revenue for the last year?▼
Aclaris Therapeutics revenue for the last year amounts to 37.44M USD.
What is Aclaris Therapeutics net income for the last year?▼
ACRS net income for the last year is -264.13M USD.
How many employees does Aclaris Therapeutics have?▼
As of April 02, 2026, the company has 61 employees.
In which sector is Aclaris Therapeutics located?▼
Aclaris Therapeutics operates in the Health Care sector.
When did Aclaris Therapeutics complete a stock split?▼
The last stock split for Aclaris Therapeutics was on November 09, 2015 with a ratio of 6:5.
Where is Aclaris Therapeutics headquartered?▼
Aclaris Therapeutics is headquartered in Wayne, US.